Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage
European Journal of Clinical Pharmacology · 2025-02 · 81 (2) · 237-246
DOI: 10.1007/s00228-024-03784-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 30.11.2024. Verfasst von Ping Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Bishan Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Hemorrhage, Nebulizers and Vaporizers. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Bishan District, China.
Abstract (Originalsprache)
PURPOSE: Pulmonary hemorrhage is a life-threatening condition characterized by blood leakage into lung tissues, leading to severe respiratory distress. Nebulized tranexamic acid (TXA) has emerged as a promising treatment option for pulmonary hemorrhage due to its localized hemostatic effects and minimal systemic side effects. This review aims to summarize the research progress on the effectiveness and safety of nebulized TXA in pulmonary hemorrhage. METHODS: A comprehensive search of the Embase, PubMed, and Scopus databases was conducted to identify relevant studies published between the date of inception of each database and November 2023. A comprehensive search was conducted in the PubMed, Embase, Scopus, and Google Scholar databases using the following keywords: "hemoptysis," "haemoptysis," "pulmonary hemorrhage," "tranexamic acid," "antifibrinolytic," "nebulize," and "inhale." Additional articles were identified by reviewing the references of the retrieved studies. Studies were selected based on their focus on the application of nebulized TXA for pulmonary hemorrhage. The authors and dates of publication, study type, patients, diseases, intervention and main outcomes of these papers are tabulated. This consisted of two randomized controlled trials (RCTs), six case series, and nine case reports. RESULTS: The commonly used dosage of nebulized TXA in the studies reviewed was 500 mg/5 ml, administered 3-4 times daily. Evidence suggests that nebulized TXA effectively controls bleeding in pulmonary hemorrhage with a hemostatic efficacy comparable to systemic administration, but with a lower risk of venous thrombosis. Safety data indicates that nebulized TXA is generally well-tolerated, with no significant systemic adverse reactions reported. Local reactions, such as bronchospasm, were rare and resolved with short-term bronchodilator treatment. CONCLUSION: Nebulized TXA appears to be an innovative and minimally invasive therapy for pulmonary hemorrhage, providing targeted hemostatic effects with a favorable safety profile. However, the predominance of small-scale studies and case reports highlights the need for large-scale, high-quality research to establish standardized guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Bishan Hospital of Chongqing Medical University, Chongqing, China.
- Department of Cardiology, Bishan Hospital of Chongqing Medical University, Chongqing, China. 419870406@qq.com.
Förderung
- Science and Technology Project of Bishan District, China
Zitieren
APA
Zhang, P., Zheng, J., Shan, X., & Zhou, B. (2025). Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage. European Journal of Clinical Pharmacology, 81(2), 237-246. https://doi.org/10.1007/s00228-024-03784-5
Vancouver
Zhang P, Zheng J, Shan X, Zhou B. Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage. European Journal of Clinical Pharmacology. 2025;81(2):237-246. doi:10.1007/s00228-024-03784-5
BibTeX
@article{Zhang2025,
author = {Zhang, Ping and Zheng, Jiaoni and Shan, Xuefeng and Zhou, Bo},
title = {Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage},
journal = {European Journal of Clinical Pharmacology},
year = {2025},
volume = {81},
number = {2},
pages = {237--246},
doi = {10.1007/s00228-024-03784-5}
}
EUVIMED